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550 Abstracts August 2013compared outcomes for AVFs and AVGs in patients with equivalent vascular
anatomy who were also receiving dialysis through a catheter at the time of
vascular access placement. Patients who underwent a ﬁrst-time AVF or AVG
between 2006 and 2009, who were on dialysis through a catheter at the
time of access placement, and who had favorable arterial and venous
anatomy (>3 mm) were compared. The study included 89 AVFs and 59
AVG patients who met study inclusion criteria. Similar secondary patency
was achieved by AVGs and AVFs at 12 months (72% vs 71%) and 24 months
(57% vs 62%), respectively (P ¼ .96). Interventions required to maintain
patency for AVFs (n ¼ one; range, zero-10) and AVGs (n ¼ one; range,
zero-11) were not different (P ¼ .36). The number of catheter days to ﬁrst
access use was more than doubled in the AVF group (mean, 81 days)
compared with the AVG group (mean, 38 days; P < .001).
Comment: This is a relatively small retrospective single-center study
and, as the authors point out, cannot be used to conclude outcomes for
AVFs and AVGs are equivalent. Nor should we conclude from this report
that efforts to increase the prevalence of AVFs vs AVGs should cease.
Rather, the study points out that in speciﬁc patient populations, under
very speciﬁc circumstances, blind adherence to the principals of the Fistula
First Initiative may actually be detrimental for patients. What are needed
are evidence-based algorithms for hemodialysis access in the patient
requiring renal replacement therapy. Such algorithms need to take into
account a multitude of variables that effect maturation and patency of
AVFs. Perhaps a risk factor-based predictive model of outcomes for AVFs
could be developed that is methodologically similar to the one purposed
for carotid endarterectomy by Bekelis et al, also featured in this abstract
section of the Journal.Association of Perioperative b-Blockade With Mortality and
Cardiovascular Morbidity Following Major Noncardiac Surgery
London MJ, Hur K, Schwartz GG, et al. JAMA 2013;309:1704-13.
Conclusion: Among propensity-matched patients undergoing
noncardiac, nonvascular surgery, perioperative b-blocker exposure was asso-
ciated with lower rates of 30-day all-cause mortality in patients with two or
more Revised Cardiac Risk Index factors. No association between b-blocker
exposure and outcome in patients undergoing vascular surgery could be
demonstrated.
Summary: Current class I recommendations of the American Heart
Association/American College of Cardiology Foundation Guidelines on
Perioperative Evaluation and Care for Noncardiac Surgery with respect to
b-blockers remain limited to continuation of pre-existing b-blocker therapy
(Fleisher LA et al, Circulation 2009;120:e169-276). Studies addressing the
use of perioperative b-blockade for noncardiac surgery differ with respect to
whether in-hospital perioperative b-blockade can reduce cardiovascular
events in patients undergoing noncardiac surgery. In addition, recent
evidence suggests the use of perioperative b-blockade may be declining
(Wijeysundera DN, Circ Cardiovasc Qual Outcomes 2012;5:558-65).
This perhaps reﬂects recent studies questioning the efﬁcacy of long-term
b-blockade in the stable outpatient (Devereaux PJ et al, Lancet
2008;371:1839-47). Given recent trends in downward use of b-blockade,
the authors sought to determine early perioperative outcomes with and
without early perioperative exposure to b-blockers by using 30-day postop-
erative outcomes in patients undergoing noncardiac surgery. This retrospec-
tive cohort analysis evaluated exposure to b-blockers on the day of or after
major noncardiac surgery. The study was a population-based sample of
136,745 patients who were 1:1 matched on propensity scores (37,805
matched pairs) and who were treated at 104 Department of Veterans Affairs
medical centers from January 2005 through August 2010. The main
outcome measure was all cause 30-day mortality and cardiac morbidity
(cardiac arrest or Q-wave myocardial infarction). Overall 55,138 patients
(40.3%) were exposed to b-blockers. Vascular surgical patients had the high-
est b-blocker exposure, 67.7% of 13,863 patients undergoing vascular
surgery (95% conﬁdence interval [CI], 65.9%-67.5%). Of the 122,882
patients undergoing nonvascular surgery, b-blocker exposure was 37.4%
(95% CI, 37.1%-37.6%; P < .001). With increasing numbers of Revised
Cardiac Risk Index factors, b-blocker exposure increased: 25.3% (95% CI,
24.9%-25.6%) in those with no risk factors vs 71.3% (95% CI, 69.5%-
73.2%) in those with four or more risk factors (P < .001). Death occurred
among 1.1% and cardiac morbidity among 0.9% of patients. In the propen-
sity-matched cohort, b-blocker exposure was associated with lower
mortality (relative risk [RR], 0.73; 95% CI, 0.65-0.83; P < .001; number
needed to treat [NNT], 241; 95% CI, 173-397). When stratiﬁed by cumu-
lative numbers of Revised Cardiac Risk Index factors, b-blocker exposure
was associated with signiﬁcantly lower mortality among patients with two
factors (RR, 0.63; P < .001; NNT, 105), three factors (RR, 0.54; P <
.001; NNT, 41), or four factors or more (RR, 0.40; P < .001; NNT,
18). b-blocker exposure was also associated with a lower rate of nonfatalQ-wave infarction or cardiac arrest (RR, 0.67; P < .001; NNT, 339). No
association could be demonstrated between b-blocker exposure and
outcomes in vascular surgical patients with respect to mortality at 30 days
and cardiac morbidity.
Comment: Among patients undergoing noncardiac surgery, vascular
surgery patients are generally considered at the highest risk of mortality
and cardiac morbidity. However, in this large and well-performed analysis,
b-blocker exposure did not inﬂuence outcomes in vascular surgical patients.
This may relate to a relatively small sample size compared with the nonvas-
cular surgical cohort or to the possibility patients received medications not
captured by the electronic database that was analyzed. In addition, vascular
surgical patients may have received a higher level of postoperative care (inten-
sive care unit utilization) than nonvascular patients. The American Heart
Association/American College of Cardiology Foundation recommendation
to continue perioperative b-blockade in patients undergoing noncardiac
vascular surgery who are already taking b-blockers seems reasonable. Unfor-
tunately, this study does not indicate the potential beneﬁt of new institution
of perioperative b-blockade in patients undergoing vascular surgery.Inﬂammation in Complex Regional Pain Syndrome: A Systematic
Review and Meta-Analysis
Parkitny L, McAuley JH, Di Pietro F, et al. Neurology 2013;80:106-17.
Conclusions: Complex regional pain syndrome (CRPS) is associated
with a proinﬂammatory state in blood, blister ﬂuid, and cerebral spinal ﬂuid
(CSF). Acute and chronic cases have different inﬂammatory proﬁles.
Summary: Clinically, CRPS is characterized by allodynia, severe pain,
hyperalgesia, and autonomic signs and symptoms (Marinus J et al, Lancet
Neurol 2011;10:637-48). The precise underlining mechanisms resulting
in CRPS are unknown; however, a number of studies have suggested an
inﬂammatory state of some sort characterizes both acute and chronic
CRPS (Huygen FJ et al, Immunol Lett 2004;91:147-154; and Groenweg
JG et al, BMC Musculoskelet Disord 2006;7:91). Identiﬁcation of speciﬁc
inﬂammatory modulators in acute and chronic forms of CRPS could guide
therapy to modify speciﬁc inﬂammatory states and, potentially, improve
CRPS symptoms. The authors therefore conducted a systematic review
and meta-analysis to determine whether CRPS is associated with a speciﬁc
inﬂammatory proﬁle. They also sought to determine whether such an
inﬂammatory proﬁle might be dependent on duration of the condition. A
comprehensive search of the literature using online databases was per-
formed. Articles that measured inﬂammatory factors in CRPS were identi-
ﬁed. Two independent investigators screened titles and abstracts and also
performed data extraction and risk of bias assessments. Studies were group-
ed by medium of ﬂuid analyzed (blood, blister ﬂuid, and CSF) and duration
of the CRPS condition (acute vs chronic). When possible, meta-analysis of
inﬂammatory factor concentrations was performed. Pooled effect sizes were
calculated using random-effects models. The authors identiﬁed 22 studies
for the systematic review and included 15 in the meta-analysis. In acute
CRPS, the concentration of interleukin (IL)-8 and soluble tumor necrosis
factor receptors I and II were increased signiﬁcantly in blood. In chronic
CRPS, there were (1) signiﬁcant increases in tumor necrosis factor-a, brady-
kinin, soluble (s)IL-IRI, IL-IRa, IL-2, sIL-2Ra, IL-4, IL-7, interferon-g,
monocyte chemoattractant protein-1, and soluble receptor for advanced
glycation end products in blood; (2) IL-IRa, monocyte chemoattractant
protein-I, macrophage inﬂammatory protein-Ib, and IL-6 in blister ﬂuid;
and (3) IL-Ib and IL-6 in CSF. Chronic CRPS was also associated with
signiﬁcantly decreased substance P, sE-selectin, sL-selectin, sP-selectin,
and sGPI30 in blood. There were also decreased levels of soluble intercel-
lular adhesion molecule-I in CSF.
Comment: The ﬁndings indicated that CRPS is associated with
a proinﬂammatory state both acutely and chronically. In addition, the
inﬂammatory states differ in the acute and chronic phase of CRPS. Sympa-
thectomy is often considered in the management of CRPS, but long-term
results are inconsistent. The data suggest that medical management of
CRPS targeting speciﬁc proinﬂammatory states has potential therapeutic
efﬁcacy. Whether this potential translates into clinical efﬁcacy or could be
combined with sympathectomy to improve management of CRPS will
require additional investigation.Blood Transfusion for Lower Extremity Bypass Is Associated with
Increased Wound Infection and Graft Thrombosis
Tze-Woei T, Farber A, Hamburg NM, et al., Vascular Study Group of New
England. JAMA 2013;216:1005-14.
Conclusion: Transfusion perioperatively in patients undergoing lower
extremity bypass (LEB) is associated with increased perioperative graft
thrombosis and wound infection.
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factor for adverse patient outcomes. In cardiac surgery in particular, perio-
perative transfusion of packed red blood cells (RBCs) has been associated
with increased mortality, postoperative ischemic morbidity, increased cost,
and increased severe postoperative bacterial infections (Leal-Noval SR,
Chest 2001;119:1461-8). Data on the effect of transfusion in vascular
surgical patients after vascular surgical procedures are less robust than that
after cardiac surgery. In this study, the authors used the Vascular Study
Group of New England database to examine patients with LEB. Speciﬁcally,
they sought to analyze the association of intraoperative and postoperative
blood transfusion with 30-day and midterm outcomes that included patient
survival, wound infection, and LEB graft patency. The Vascular Study
Group of New England database was queried from 2003 to 2010 for
LEB operations. There were 1880 infrainguinal LEBs performed for critical
limb ischemia. Perioperative transfusion was categorized as 0 units (U), 1 to
2 U, and $3 U. Cohort frequency group matching was used to compare
patients receiving 1 to 2 U or 0 U with patients receiving$3 U. Corrections
were for age, coronary artery disease, diabetes, urgency, and indication of
revascularization. Primary end points were perioperative mortality, wound
infection, and loss of primary graft patency at discharge; 1-year mortality;
and loss of primary graft patency during the ﬁrst postoperative year. There
were 1532 LEBs (81.5%) that received 0 U of transfusion, 248 LEBs
(13.2%) that received 1 to 2 U, and 100 LEBs (5.3%) that received $3
U. In the study cohort and group frequency-matched cohort, transfusion
was associated with higher perioperative wound infection of 4.8% for 0 U
vs 6.5% for 1 to 2 U vs 14.0% $3 U (P ¼ .0004) and was also associated
with graft thrombosis at discharge of, respectively, 4.5% vs 7.7% vs 15.3%
(P < .0001). No differences in infection or graft patency were noted at 1
year. Multivariate analysis showed transfusion was independently associated
with increased perioperative wound infection in the study cohort and group
frequency-matched cohort (1 to 2 U vs 0 U: adjusted odds ratio [OR], 1.4;
95% conﬁdence interval [CI], 0.8-2.5; P ¼ .263; $3 U vs 0 U: OR, 3.5;
95% CI, 1.8-6.7; P ¼ .0002; overall P ¼ .002). Finally, transfusion was asso-
ciated with graft thrombosis at discharge (1 to 2 U vs 0 U: OR, 2.1; 95% CI,
1.2-3.6; P ¼ .01; $3 U vs 0 U: OR, 4.8; 95% CI, 2.5-9.2; P < .0001; over-
all P < .0001).
Comment: This is one of the ﬁrst studies to look at the signiﬁcance of
transfusion in LEB patients. However, despite the excellent statistical meth-
odology used, this is still a retrospective study of voluntarily contributed
data. It is not a randomized controlled trial. Therefore, we do not truly
know whether there are unknown confounders associated with the adjust-
ments that might contribute to a greater degree in the statistical outcome
of one group vs another. The very fact that patients receiving transfusions,
especially $3 U, also lost more blood, despite matching other characteris-
tics, strongly suggest there may be something different about the operations
that had increased transfusions vs those that did not.A Risk Factor-Based Predictive Model of Outcomes in Carotid
Endarterectomy: The National Surgical Quality Improvement
Program 2005-2010
Bekelis K, Bakhoum SF, Desai A, et al. Stroke 2013;44:1085-90.
Conclusion: Patient-level characteristics dramatically inﬂuence risk of
carotid endarterectomy (CEA). Models based on patient-level characteris-
tics, however, cannot be used for individual patient risk assessment because
of limited discriminatory ability.
Summary: Results of the randomized trials of CEA directly apply only
to those meeting inclusion and exclusion criteria for the trials. Patients were
generally considered to have had low overall operative risk and to have met
predeﬁned age ranges for inclusion in the trials. It would be useful to
compare estimated risk of adverse events in individual patients in routine
clinical practice with benchmarks for the performance of CEA. Studies in
the past have generally been retrospective analysis of individual institutional
experiences, thus limiting general applicability because of inherent selection
bias. The American College of Surgeons (ACS) National Quality Improve-
ment Program (NSQIP) database contains prospective data from >180
private and academic hospitals across the United States. The authors used
this database to develop a risk factor-based predictive model of negative
outcomes for CEA. The hope is to better quantify risk of the individual
patient being considered for CEA. This was a retrospective cohort studyinvolving patients undergoing CEA from 2005 to 2010 who were registered
in NSQIP. There were 35,698 CEA patients: 20,015 (56.15%) were asymp-
tomatic and 15,683 (43.9%) were symptomatic. At 30 days after CEA,
patients demonstrated a 1.64% stroke risk, 0.69% risk of myocardial infarc-
tion (MI), and a 0.75% risk of death. Multivariate analysis indicated male
sex, increased age, history of chronic pulmonary disease, MI, congestive
heart failure, peripheral vascular disease, previous stroke, transient ischemic
attack, and dialysis-dependence were all independent risk factors associated
with an increased risk of the combined outcome of postoperative stroke,
MI, or death after CEA. A validated model for outcome prediction based
on individual patient characteristics was developed. There was a steep effect
of age on the risk of MI and death. Additional analysis indicated the model
could predict the risk of stroke, MI, death, or the composite outcome for
patients in the NSQIP cohort. However, the model exhibited only modest
discrimination, with an inadequate C statistical value indicating that it
cannot be used for individual patient decision making.
Comment: One might ask if the model cannot be used to help make
individual decisions for patients, of what use is the model? The primary use
would appear to be development of risk-prediction models for populations
of patients, individual hospitals, or health care systems. The model, there-
fore, may be used for risk predications for patient populations and therefore
could provide an objective bases for observed to expected complication
rates.Trends in Treatment of Ruptured Abdominal Aortic Aneurysm:
Impact of Endovascular Repair and Implications for Future Care
Park BD, Azefor N, Huang C-C, et al. J Am Coll Surg 2013;216:745-55.
Conclusions: Endovascular repair of ruptured abdominal aortic aneu-
rysm (RAAA) is more common in urban teaching hospitals and is associated
with reduced mortality and complications across all age groups. No therapy
for RAAA is more common in rural hospitals.
Summary: Marin et al reported endovascular aneurysm repair
(EVAR) for RAAA in 1994 (Ann Surg 1995;222:449-65). Since that
time, a number of anecdotal series have suggested that at an individual insti-
tution level, EVAR can result in decreased mortality associated with RAAA,
and EVAR for repair of RAAA is being used with increased frequency across
the United States during the last decade. In this report, the authors sought
to document recent trends in the management of RAAA in the United
States. They speciﬁcally wished to examine use of EVAR for treatment of
RAAA and to draw some implications from these ﬁndings for future care
of patients with RAAA. Data for this study were obtained from the Nation-
wide Inpatient Sample from 2005 to 2009. Identiﬁed patients aged >59
years with RAAA were included. Three groups were studied: nonoperative
(NO), EVAR, and open surgical repair (OSR) for RAAA. The relationship
between treatment type, patient demographics, clinical characteristics, and
hospital type was determined with c2 analysis. Logistic regression analysis
was used to examine EVAR compared with OSR on mortality and overall
complications of RAAA. Of 21,206 patients with RAAA identiﬁed from
2005 to 2009, 16,558 (78.1%) underwent operative repair and 21.8%
received no operative treatment. Among the operatively treated patients,
12,761 (71.1%) underwent OSR and 3,796 (22.9%) underwent EVAR.
EVAR was more common in teaching hospitals (29.1% vs 15.2%, P <
.0001) and in urban vs rural settings. In the rural setting, a nonoperative
approach was twice as common as in the urban setting. Reduced mortality
was seen in patients transferred from one institution to another (31.2% v
39.4%, P ¼ .014). EVAR was associated with a lower complication rate
(odds ratio, 0.492; conﬁdence interval, 0.380-0.636) and decreased
mortality (odds ratio, 0.535; conﬁdence interval, 0.395-0.724).
Comment: The authors believe EVAR should be offered whenever
possible to patients with RAAA. However, like any retrospective series, these
data are subject to potentially heavy selection bias. In addition, a number of
parameters associated with operative mortality for RAAA cannot be
analyzed with the Nationwide Inpatient Sample database. These include
shock, oliguria, and preoperative state of consciousness. Nevertheless, the
data do provide a snapshot of the state of RAAA repair in the United States
and suggest mortality may be reduced through increasing the use of EVAR
for treatment of RAAA. In addition, the number of turndowns for repair of
RAAA may be able to be reduced by more efﬁcient transportation systems
to centers of excellence that use EVAR for treatment of RAAA.
